Risk Sharing Agreements in the Asia-Pacific Region: A Systematic Literature Review on New Pricing Modalities to Improve Value Access
Author(s)
Verma A1, Rai MK2, Prasanna R1
1EVERSANA, Mumbai, MH, India, 2EVERSANA, Singapore, Singapore, Singapore
Presentation Documents
OBJECTIVES: The concept of risk sharing agreements (RSA) in the field of health policy and reimbursement decision-making is still relatively new in the Asia-Pacific region (APAC). By analyzing existing RSA types, the objective of this study was to identify new pricing modalities that can be implemented in APAC countries.
METHODS: A comprehensive search was conducted through Medline/PubMed and grey literature sources (such as online reports, conference presentations, and non-academic/indexed journals) until May 2023. The search employed a combination of relevant keywords, including 'outcome-based agreements,' 'risk sharing,' 'managed entry agreements,' 'indication value-based pricing,' 'conditional reimbursement,' 'multiple indication pricing,' 'drug combination pricing,' and 'patient access schemes,' within the period of 2000 to 2023. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were also followed as reporting guidelines.
RESULTS: Out of 1300 citations identified from PubMed/Medline searches and 87 from conferences and cross-referencing, 25 articles met the inclusion criteria and were selected for data extraction and final analyses. Among the included studies, price-volume agreements emerged as the most frequently studied RSA type, accounting for 14 of the included studies, followed by outcome-based RSA, which constituted 11 studies. Within APAC region, Australia exhibited the highest likelihood of adopting managed entry schemes, followed by Taiwan and South Korea. However, in other countries, the current healthcare structures and policies present challenges that hinder the nationwide implementation of outcomes-based schemes.
CONCLUSIONS: Over the past decade, interest in RSAs has grown in APAC countries, presenting significant implications for healthcare policymaking. However, there is currently no universally accepted approach for employing new pricing modalities to enhance value access in RSAs. Further research is necessary to develop theoretical frameworks and practical models that can support the widespread adoption of RSAs across the region.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
HPR123
Topic
Clinical Outcomes, Health Policy & Regulatory, Study Approaches
Topic Subcategory
Literature Review & Synthesis, Performance-based Outcomes, Pricing Policy & Schemes, Risk-sharing Approaches
Disease
No Additional Disease & Conditions/Specialized Treatment Areas